Literature DB >> 15837371

CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the CD40 signal to B cells, but does not substitute for T cell help in responses to TD antigens.

Tom A Barr1, Jennifer Carlring, Andrew W Heath.   

Abstract

Agonistic antibodies against CD40 have great potential as immunological adjuvants. We have shown that CD40mAbs induce strong antibody responses against conjugated antigen, and that this enhancement of responses extends to any sequence physically associated to the CD40 binding moiety, including the antibody's own Fc region. Thus, the CD40mAb acts as a model immunogen, containing both antigenic (i.e. Fc portion) and CD40 binding motifs (i.e. CD40 binding moiety). Using this system we examine here whether CD40mAb is able to directly mimic T cell help to B cells. CD40mAbs have no adjuvant effect in CD4 depleted mice, and thus, do not mimic T cell help. Simultaneous administration of recombinant IL-4 was unable to restore the adjuvant action of anti-CD40 in T cell depleted mice. However, CD40mAbs are effective adjuvants in CD154-/- mice, indicating that the antibodies are able to provide the CD40 stimulus to B cells which is naturally lacking in these mice. Identification of the additional stimuli required to fully mimic T cell help may be advantageous in vaccination of immunosuppressed patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837371     DOI: 10.1016/j.vaccine.2004.12.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  CD40-mediated enhancement of immune responses against three forms of influenza vaccine.

Authors:  Caterina Hatzifoti; Andrew W Heath
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

2.  B cells in murine cervical lymph nodes are conventional B-2 cells.

Authors:  Seung Geun Yeo; Joong Saeng Cho; Dong Choon Park
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

3.  CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis.

Authors:  Vijay Ns Bhagawati-Prasad; Evy De Leenheer; Nadine P Keefe; Lorna A Ryan; Jennifer Carlring; Andrew W Heath
Journal:  J Immune Based Ther Vaccines       Date:  2010-02-04

4.  In the absence of CD154, administration of interleukin-12 restores Th1 responses but not protective immunity to Schistosoma mansoni.

Authors:  James P Hewitson; Paul A Hamblin; Adrian P Mountford
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

5.  Distinct roles of CD28- and CD40 ligand-mediated costimulation in the development of protective immunity and pathology during Chlamydia muridarum urogenital infection in mice.

Authors:  Lili Chen; Wen Cheng; Pooja Shivshankar; Lei Lei; Xiaoyun Zhang; Yimou Wu; I-Tien Yeh; Guangming Zhong
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

6.  Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.

Authors:  Sachin Gupta; James M Termini; Francesca N Raffa; Cindi-Ann Williams; Richard S Kornbluth; Geoffrey W Stone
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

7.  A novel redox method for rapid production of functional bi-specific antibodies for use in early pilot studies.

Authors:  Jennifer Carlring; Evy De Leenheer; Andrew William Heath
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

8.  Co-administration of a plasmid encoding CD40 or CD63 enhances the immune responses to a DNA vaccine against bovine viral diarrhea virus in mice.

Authors:  Dongze Leng; Shinji Yamada; Yusuke Chiba; Syuji Yoneyama; Yusuke Sakai; Hirokazu Hikono; Kenji Murakami
Journal:  J Vet Med Sci       Date:  2022-07-07       Impact factor: 1.105

9.  Liposomal co-entrapment of CD40mAb induces enhanced IgG responses against bacterial polysaccharide and protein.

Authors:  Caterina Hatzifoti; Andrew Bacon; Helen Marriott; Peter Laing; Andrew W Heath
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.